Eli Lilly and Company

Vertex Pharmaceuticals, Inc.

Other

Cristina Garcia-paredes

Ivan Collado

Mark Joseph Tebbe

Deqi Guo

Ling Jin

John Irvin Glass

Q. May Wang

Xicheng David Sun

Raymond Samuel, III Parker

Frantz Victor

Yvonne Yee Mai Yip

Robert Edward Babine

Nancy June Snyder

Owen Brendan Wallace

Yanping Xu

Thomas Edward Mabry

Robin D Cooper

Leonard Larry Winneroski, Jr

Michael J Rodriguez

Thomas Daniel Aicher

Richard Craig Thompson

Bret E Huff

Stephen Charles Wilkie

Michael A Staszak

Renhua Li

Luc J Farmer

Robert B Perni

John Michael Morin, Jr

Ronald Jay Hinklin

Michael Dean Kinnick

Jefferson Ray McCowan

Jeremy Schulenburg York

Lawrence Joseph Heinz, Ii

Zhaogen Chen

James Ronald Gillig

Mark Joseph Chicarelli

Philip Arthur Hipskind

Theo Schotten

John Gordon Allen

Kenneth Allen Savin

Robert F Snyder

Peter Biagio Anzeveno

James Arthur Nixon

Marvin M Hansen

Gregory Alan Stephenson

Mark J Zweifel

Q May Wang

Jason Eric Lamar

Ashraf Saeed

Cristina Garcia-Paredes

Alexei Pavlovych Krasutsky

Thalia I Nicas

John T Quatroche

Raymond Samuel Parker, Iii

Hongqi Tian

Yen-Shi Lai

Shu Hui Chen

Julie Kay Bush

Gary A Hite

James Lee Toth

Michael Alan Robertson

Carsten Ott

Shu-Hui Chen

Jochen Ammenn

Rebecca Lynn Rezac Guenther

Lawrence John Slieker

Larry Leonard Winneroski

Marvin Martin Hansen

Deqi Duo

Samuel Raymond Iii Parker

Raymond Samuel Iii Parker

Rebecca Lynn Guenther

Junior Leonard Larry Winneroski

Gary Alan Hite

Samuel Raymond Parker Iii

Mai Yee Yvonne Yip

Leonard Larry Junior Winneroski

Iii Parker Raymond Samuel

May Q Wang

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

Peptidomimetic protease inhibitors

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.

The present invention discloses novel compounds of Formula I: (I) having 11-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11-HSD type 1 activity. 

Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula I: having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I), as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention discloses novel compounds of Formula (I): having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

The present invention discloses novel compounds of Formula I: (I) having 11&#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, and other conditions associated with 11&#x3b2;-HSD type 1 activity. 

Cyclohexylimidiazole lactam derivatives as inhibitors of 11-&#x3b2;-hydroxysteroid dehydrogenase 1

The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia. 

Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes

The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar, Ar, Ar, L, Land Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases 

MCH receptor antagonists

A thermal insulation sheet is maneuvered into position, especially in closely confined corners in an attic, by a tool having a prong which is inserted into the sheet, and a pusher surface which contacts the sheet to limit the depth of insertion of the prong, and which guides the sheet while an installer pushes the pusher surface against the sheet while maintaining the prong in the sheet.

Method of and instrument or arrangement for installing thermal insulation sheets in confined areas

The present invention provides glycopeptide antibiotic derivative compounds. These derivative compounds possess antibacterial activity against a wide variety of bacteria, including activity against vancomycin-resistant isolates. Methods of making and using these glycopeptide antibiotic derivative compounds are also provided.

Glycopeptide antibiotic derivatives

The present invention is directed to amides of antibiotic A82846B (also known as chloroorienticin A), and of N.sup.4 -derivatives of A82846B. The present amide compounds are useful as antibacterials, especially for the control of gram positive bacteria; the compounds are particularly useful for the control of resistant bacterial strains, such as vancomycin-resistant-enterococci ('VRE').

Amides

Growing community of inventors

Lizton, IN, United States of America

Nancy June Snyder